CoChat

Effect of Gastric Bypass vs Best Medical Treatment on Early-Stage Chronic Kidney Disease in Patients With Type 2 Diabetes and Obesity: A Randomized Clinical Trial

Open access
Cohen, Ricardo Vitor, Pereira, Tiago Veiga, Aboud, Cristina Mamédio, Petry, Tarissa Beatrice Zanata, Lopes Correa, José Luis, Schiavon, Carlos Aurélio, Pompílio, Carlos Eduardo, Pechy, Fernando Nogueira Quirino, da Costa Silva, Ana Carolina Calmon, de Melo, Fernanda Lendimuth Gomes, Cunha da Silveira, Lívia Porto, de Paris Caravatto, Pedro Paulo, Halpern, Helio, Monteiro, Frederico de Lima Jacy, da Costa Martins, Bruno, Kuga, Rogerio, Palumbo, Thais Mantovani Sarian, Docherty, Neil Gerard, le Roux, Carel Wynand · 2020 · JAMA Surgery
Cited by 156

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Importance: Early-stage chronic kidney disease (CKD) characterized by microalbuminuria is associated with future cardiovascular events, progression toward end-stage renal disease, and early mortality in patients with type 2 diabetes. Objective: To compare the albuminuria-lowering effects of Roux-en-Y gastric bypass (RYGB) surgery vs best medical treatment in patients with early-stage CKD, type 2 diabetes, and obesity. Design, Setting, and Participants: For this randomized clinical trial, patients with established type 2 diabetes and microalbuminuria were recruited from a single center from April 1, 2013, through March 31, 2016, with a 5-year follow-up, including prespecified intermediate analysis at 24-month follow-up. Intervention: A total of 100 patients with type 2 diabetes, obesity (body mass indexes of 30 to 35 [calculated as weight in kilograms divided by height in meters squared]), and stage G1 to G3 and A2 to A3 CKD (urinary albumin-creatinine ratio [uACR] >30 mg/g and estimated glomerular filtration rate >30 mL/min) were randomized 1:1 to receive best medical treatment (n = 49) or RYGB (n = 51). Main Outcomes and Measures: The primary outcome was remission of albuminuria (uACR <30 mg/g). Secondary outcomes were CKD remission rate, absolute change in uACR, metabolic control, other microvascular complications, quality of life, and safety. Results: A total of 100 patients (mean [SD] age, 51.4 [7.6] years; 55 [55%] male) were randomized: 51 to RYGB and 49 to best medical care. Remission of albuminuria occurred in 55% of patients (95% CI, 39%-70%) after best medical treatment and 82% of patients (95% CI, 72%-93%) after RYGB (P = .006), resulting in CKD remission rates of 48% (95% CI, 32%-64%) after best medical treatment and 82% (95% CI, 72%-92%) after RYGB (P = .002). The geometric mean uACRs were 55% lower after RYGB (10.7 mg/g of creatinine) than after best medical treatment (23.6 mg/g of creatinine) (P < .001). No difference in the rate of serious adverse events was observed. Conclusions and Relevance: After 24 months, RYGB was more effective than best medical treatment for achieving remission of albuminuria and stage G1 to G3 and A2 to A3 CKD in patients with type 2 diabetes and obesity. Trial Registration: ClinicalTrials.gov Identifier: NCT01821508.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamasurg.2020.0420

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 156

Metadata

Authors
Cohen, R. V., Pereira, T. V., Aboud, C. M., Petry, T. B. Z., Lopes Correa, J. L., Schiavon, C. A., Pompílio, C. E., Pechy, F. N. Q., da Costa Silva, A. C. C., de Melo, F. L. G., Cunha da Silveira, L. P., de Paris Caravatto, P. P., Halpern, H., Monteiro, F. D. L. J., da Costa Martins, B., Kuga, R., Palumbo, T. M. S., Docherty, N. G., & le Roux, C. W.
Venue
JAMA Surgery
Published
2020-08-19
Volume
155
Issue
8
Pages
e200420
ISSN
2168-6254 (ISSN-L)
OpenAlex
W3032841523
Cited by
156
References
14
FWCI
20.13
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Gastric Bypass vs Best Medical Treatment on Early-Stage Chronic Kidney Disease in Patients With Type 2 Diabetes and Obesity: A Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jamasurg.2020.0420
The paper
Cohen, R. V., Pereira, T. V., Aboud, C. M., Petry, T. B. Z., Lopes Correa, J. L., Schiavon, C. A., Pompílio, C. E., Pechy, F. N. Q., da Costa Silva, A. C. C., de Melo, F. L. G., Cunha da Silveira, L. P., de Paris Caravatto, P. P., Halpern, H., Monteiro, F. D. L. J., da Costa Martins, B., Kuga, R., Palumbo, T. M. S., Docherty, N. G., & le Roux, C. W. (2020). Effect of Gastric Bypass vs Best Medical Treatment on Early-Stage Chronic Kidney Disease in Patients With Type 2 Diabetes and Obesity: A Randomized Clinical Trial. JAMA Surgery. https://doi.org/10.1001/jamasurg.2020.0420

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.